Kineta. has filed a patent for compositions and methods to treat neurological disorders like ALS, frontotemporal degeneration, and Alzheimer’s disease by administering a PIKfyve inhibitor. The treatment targets TDP-43 aggregation, offering potential relief for patients susceptible to developing related disorders. GlobalData’s report on Kineta gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Kineta, Peptide pharmacophores was a key innovation area identified from patents. Kineta's grant share as of January 2024 was 25%. Grant share is based on the ratio of number of grants to total number of patents.
Treating neurological disorders with pikfyve inhibitors
See Also:
A recently filed patent (Publication Number: US20240016810A1) discloses methods for treating neurological disorders in human patients by administering a PIKfyve inhibitor. The first claim involves treating a neurological disorder in a patient who does not express a mutant form of c9orf72 with an expanded GGGGCC hexanucleotide repeat. The second claim focuses on treating a neurological disorder in a patient susceptible to developing TAR-DNA binding protein (TDP)-43 aggregation by administering a PIKfyve inhibitor. Additionally, the patent covers various neuromuscular disorders and other neurological conditions such as frontotemporal degeneration, Alzheimer's disease, and Parkinson's disease.
The patent further details specific compounds represented by formulas (I) to (XI) that can be used as PIKfyve inhibitors for treating neurological disorders. These compounds are small molecules that bind to and/or inhibit PIKfyve enzymatic activity. The disclosed methods offer potential treatment options for a wide range of neurological disorders, including amyotrophic lateral sclerosis, Duchenne muscular dystrophy, Parkinson's disease, and Huntington's disease. By targeting specific molecular pathways associated with these conditions, the use of PIKfyve inhibitors presents a novel approach to managing and potentially improving outcomes for patients with neurological disorders.
To know more about GlobalData’s detailed insights on Kineta, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
